Paloma Partners’s GeneDx Holdings WGS Stock Holding History

Paloma Partners’s Portfolio WGS Stock Details WGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,403	Closed	-$156K	–	2282
2021 Q4	$206K	Buy	1,403 +523	+59%	+$117K	﹤0.01%	1589
2021 Q3	$220K	Buy	+880	New	+$302K	0.01%	826

Other funds holding WGS

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Paloma Partners's WGS Position: Q1 2022 in Review

Paloma Partners sold out of GeneDx Holdings (WGS) in Q1 2022, closing a stake of 1,403 shares — an estimated $156K sold.

Paloma Partners first reported a position in WGS in Q3 2021 and held it in 2 quarters. The position peaked at $220K in Q3 2021. 108 funds tracked by Wall St. Rank hold WGS as of Q1 2022.

Paloma Partners reported no remaining GeneDx Holdings position as of Q1 2022 after selling out during the quarter.
Paloma Partners sold 1,403 GeneDx Holdings shares in Q1 2022, an estimated $156K.
Paloma Partners first reported a position in GeneDx Holdings in Q3 2021 and held it in 2 quarters.
Paloma Partners's GeneDx Holdings position peaked at $220K in Q3 2021.
108 funds tracked by Wall St. Rank held GeneDx Holdings as of Q1 2022.

Based on Paloma Partners's 13F filing for Q1 2022, filed 16 May 2022.